Burning Rock Biotech
燃石医学
Executive Summary
Burning Rock Biotech is a leading Chinese precision oncology company specializing in NGS-based cancer diagnostics and companion diagnostics development. The company has established partnerships with major pharma companies and maintains a clear BIOSECURE status, making it an attractive BD target for US companies seeking CDx partnerships in China. Strong commercial presence in IVD market with growing pipeline of companion diagnostics, though limited visibility into current deal-making activities due to sparse recent event data.
Structure: Burning Rock operates through a standard VIE structure typical of Chinese biotech companies listed on NASDAQ, with Cayman Islands holding company and Chinese operating entities. The company maintains both diagnostic services operations and pharmaceutical partnerships through its subsidiaries, requiring standard VIE due diligence for any potential transactions.
Ownership & Shareholder Structure
Burning Rock Biotech → Johnson & Johnson
Burning Rock genomic diagnostics partnership with J&J for precision oncology.
BGI Genomics → Burning Rock Biotech
Both in Chinese genomics/diagnostics. BGI is designated; Burning Rock is clear.
Clinical Trials(27 total)
16
Other
3
NA
1
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06139042 | Blood drawing | RECRUITING | 1,608 | |
| NCT06204484 | CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy | NA | RECRUITING | 349 |
| NCT05996666 | Liver-cancer early detection test | UNKNOWN | 701 | |
| NCT06001099 | Gynecological Malignancies Earlystage Detection by Multi-omics Based Liquid Biopsy in Peripheral Blood: a Prospective, Extended Validation Study | UNKNOWN | 2,935 | |
| NCT05556603 | Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study | RECRUITING | 7,062 | |
| NCT05679089 | early detection test | UNKNOWN | 358 | |
| NCT05693012 | cfDNA methylation assessment | UNKNOWN | 398 | |
| NCT05501353 | no intervention | RECRUITING | 125 | |
| NCT05635630 | ctDNA and adjuvant therapy, ctDNA | NA | UNKNOWN | 110 |
| NCT05227534 | OverC multi-cancer detection blood test | NA | RECRUITING | 12,500 |
| NCT05275036 | early detection test | UNKNOWN | 493 | |
| NCT05495685 | Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study | UNKNOWN | 450 | |
| NCT05347524 | Baseline blood draw and blood-based biomarkers analyses | RECRUITING | 384 | |
| NCT05667350 | Blood drawing, Blood drawing | UNKNOWN | 492 | |
| NCT06143644 | Serial ctDNA monitoring | ACTIVE NOT RECRUITING | 220 | |
| NCT05079022 | Furmonertinib | Ph.1, Ph.2 | UNKNOWN | 50 |
| NCT04972201 | Multi-cancer early detection test | COMPLETED | 2,305 | |
| NCT04820868 | Multi-cancer early detection test | COMPLETED | 2,508 | |
| NCT04817306 | Multi-cancer early detection test | UNKNOWN | 14,026 | |
| NCT04822792 | Multi-cancer early detection test | UNKNOWN | 11,879 |
Showing 20 of 27 trials
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, indicating lower regulatory risk for US partnerships
Key Exposures:
- •VIE structure requires ongoing monitoring
- •China-based operations subject to evolving US-China policy
Mitigation: Clean BIOSECURE status suggests company has addressed primary regulatory concerns, though ongoing compliance monitoring recommended
BD Intelligence
Therapeutic Areas:
Recent Deals: Limited visibility into recent out-licensing activity based on available data
Approach: Approach through diagnostic partnerships and CDx development collaborations, leveraging their established NGS platform and regulatory experience in China
Red Flags
- ⚠Limited recent corporate event visibility may indicate reduced activity
- ⚠Incomplete key personnel data hampers relationship mapping
- ⚠Need to verify current pipeline status and competitive positioning
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 27
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 2
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (27 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.